95 results about "Intestinal Lipase Inhibitor" patented technology

This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (+) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

The invention relates to nanoparticulate lipase inhibitor compositions having improved pharmacokinetic profiles. The nanoparticulate lipase inhibitor compositions have an effective average particle size of less than about 2000 nm and are useful in the treatment of obesity and related diseases.

A composition includes α-cyclodextrin and at least one lipase inhibitor. A method for promoting weight loss, inhibiting weight gain, or maintaining weight in a subject in need thereof includes administering α-cyclodextrin and at least one lipase inhibitor to the subject, thereby reducing the bioavailability of ingested fat and reducing the unpleasant gastrointestinal side effects.

The present invention provides fat-binding polymers, which comprise dialkanolamine, dialkanolammonium, aminoalkylpolyol, and ammoniumalkylpolyol pendant groups for subjects in need of fat removal from the gastrointestinal tract, particularly subjects suffering from steatorrhea and / or experiencing side effects from lipase inhibitors. Patients being administered with lipase inhibitors are typically being treated for Type II Diabetes, streatorrhea, and hypertriglyceridemia. The fat binding polymers of this invention are also suitable for use with obese subjects.

A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.

This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (-) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

A stabilized flour, such as stabilized whole grain wheat flour, exhibiting unexpectedly superior extended shelf life and superior biscuit baking functionality, may be produced with or without heating to inhibit lipase by subjecting whole grains or a bran and germ fraction or component to treatment with a lipase inhibitor, such as an acid or green tea extract. Treatment with the lipase inhibitor may be performed during tempering of the whole grains or berries or during hydration of the bran and germ fraction or component.

The invention relates to a method for screening a lipase inhibitor and particularly relates to a method for screening a lipase inhibitor by using a thin-layer chromatography bioautography. The method comprises the following steps of: dissolving a sample to be tested into water and / or an organic solvent, dispensing liquid of the sample to be tested on a thin-layer plate, placing the plate in a developing agent for developing, taking out the plate, and airing the plate for later use; and dipping the obtained thin-layer plate into substrate liquid, dipping the thin-layer plate into lipase liquid after completing solvent evaporation, taking out the thin-layer plate and subjecting the thin-layer plate to an enzymatic reaction at the temperature of 20-40 DEG C, and dipping the thin-layer plate into developing agent liquid for color reaction after completing the enzymatic reaction, thereby obtaining a white and / or brown-yellow spotted result diagram with a purple background. The method for screening the lipase inhibitor has the advantages that complicated instruments and devices are not required, the operation is simple, and the testing cost is low, so that the method is suitable for general laboratories; and the sensitivity and specificity are higher than those of conventional screening methods, and screened results are visual and easily recognized and remembered.

The invention provides a compound of formula (I) as defined hereinthat is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, or diabetes and disorders and conditions associated therewith. The invention also provides a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. activity.

The invention provides compositions and methods for treating pulmonary conditions and for reducing the negative effects of pulmonary inflammation. Such compositions and methods employ protease inhibitors and a lung surfactant mixture. The compositions and methods can also include lipase inhibitors (e.g. a phospholipase inhibitors) and anti-oxidants.

The invention discloses a weight management combination for a lunch and a dinner respectively. The weight management combination is characterized by including a lunch fat-reducing composition and a dinner substitute composition, the lunch fat-reducing composition includes an amylase inhibitor, a lipase inhibitor and a fat burning promoter, the amylase inhibitor includes a white kidney bean extract, the lipase inhibitor includes EGCG, and a lipid absorption conversion inhibitor includes chitosan oligosaccharide; and the dinner substitute composition is prepared from the following components inparts by weight: 25-40 parts of casein, 12-35 parts of a whey protein, 10-15 parts of medium chain triglyceride powder, 20-25 parts of a dietary fiber, 2-5 parts of skim milk powder, 2-5 parts of complex gum and 1-3 parts of decavitamin and mineral substances. According to the weight management combination, the lunch and the dinner are organically combined, collocation is reasonable, pursuit of food can be realized, the purpose of weight loss can also be achieved on the basis of satisfying nutrition demands, and the fast diet weight management combination is provided for a great deal of lose weight people.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

A method prevents or treats diseases associated with high plasma cholesterol levels. In addition, this method reduces plasma cholesterol levels. The method comprises administering a lipase inhibitor, e.g. orlistat, and a pharmaceutically acceptable bile acid sequestrant.

The present invention provides lipase inhibitory agents comprising a gallotannin or ellagitannin component(s) isolated from teas or Tellima grandiflora as well as foods and beverages and medicines containing said inhibitory agents.The present invention provides lipase inhibitory agents comprising at least one of compounds represented by formula I below:wherein R1, R2 and R3 independently represent H or a gallic acid residue, and R4 and R5 represent H or a gallic acid residue, or R4 and R5 together form an HHDP group represented by the formula below:provided that at least two of R1 to R5 represent a gallic acid residue or when all of R1, R2 and R3 are H, R4 and R5 together form the HHDP group; as well as foods and beverages and medicines containing said lipase inhibitory agents.

This invention provides a pharmaceutical composition comprising a lipase inhibitor; a lipophilic oil absorbent selected from the group consisting of hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof; and a pharmaceutically acceptable additive, an oral formulation of a lipase inhibitor prepared there from and a method for preparing said formulation. The formulation of the present invention can minimize side effects such as oily spotting, fatty / oily stool, abdominal distension and flatus, and thus it can be advantageously used for preventing or treating obesity and hyperlipaemia.

The invention provides a pharmaceutical combination product for oral administration comprising a lipase inhibitor and a plurality of ingestible particles, said particles comprising a water-swellable or water-soluble polymeric material and a lipid material. The lipase inhibitor may be provided in the ingestible particles or separate from these. The polymeric material may be embedded in the lipid material. The invention further provides methods for preparing the pharmaceutical combination product and uses thereof.

This invention provides a pharmaceutical composition comprising a lipase inhibitor; a lipophilic oil absorbent selected from the group consisting of hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof; and a pharmaceutically acceptable additive, an oral formulation of a lipase inhibitor prepared there from and a method for preparing said formulation. The formulation of the present invention can minimize side effects such as oily spotting, fatty / oily stool, abdominal distension and flatus, and thus it can be advantageously used for preventing or treating obesity and hyperlipaemia.

A lipase inhibitor comprising as an active ingredient an extract of Ascophyllum nodosum which is a kind of brown algae can be used as a useful healthy food or food for specified health uses for the treatment and / or prevention of obesity or hyperlipemia.

The present invention relates to the isolation of and characterisation of a novel lipase inhibitor and its effect on different lipases. The present invention also relates to the use of a lipase inhibitor as a screen for lipases. The present invention also relates to the use of the inhibitor and / or lipases identified by a lipase inhibitor in food and / or feed technologies.

The invention relates to the technical field of medicine, and in particular, relates to a pharmaceutical composition containing orlistat and a plant-derived lipase inhibitor. The plant-derived lipaseinhibitor is a polyphenol lipase inhibitor extracted from tea leaves. The results of in-vitro experiments show that the interaction index of orlistat and the polyphenol lipase inhibitor in inhibitionof the activity of lipase in the molar ratio range of 1:10 to 10:1 is lower than 1, and suggest that orlistat and the polyphenol lipase inhibitor generate synergistic lipase inhibition effect. The results of animal experiments show that the control effect of the composition containing orlistat and the polyphenol lipase inhibitor on the weight of nutritional obesity rats is better than that of an orlistat group and a polyphenol lipase inhibitor single drug-administration group, and generation of the synergistic effect is further verified. In addition, the polyphenol lipase inhibitor can reducethe unpleasant gastrointestinal side effects of orlistat and alleviate adverse reactions of oil spots, fat / oil stools and the like.

This disclosure relates to compositions comprising an open-celled polymeric foam wherein the compositions are useful for sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body. The disclosure further relates to compositions comprising the open-celled polymeric foam wherein the compositions are useful for ameliorating side effects associated with the use of lipase inhibitors. In a preferred embodiment, this disclosure relates to compositions comprising polymeric foam materials made from high internal phase emulsions, where such foams are useful for sequestering lipophilic materials. Further disclosed are compositions comprising open-celled polymeric foams wherein the compositions are useful for the purpose of sequestering aqueous and / or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea. Kits comprising the compositions and methods of using the compositions and kits are also described.

The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.

The invention relates to a medicine composition containing lipoprotein-associated phospholipase A2 inhibitors and application of the medicine composition, and belongs to the technical field of medicine. The medicine composition consists of lipoprotein-associated phospholipase A2 inhibitors and one or several kinds of the following ingredients including HMG-CoA (3-hydroxyl-3-methylglutaryl CoA) reductase inhibitors, cholesterol and triglyceride metabolism influence medicine, cholesterol absorption influence medicine, polysaccharide lipid-lowering medicine, gastrointestinal lipase inhibitors or butylphenyl phthaleine. The medicine composition provided by the invention has the surprising curative effect in the aspect of treating atherosclerotic diseases, and the surprising curative effect cannot be achieved by previous lipid-lowering medicine.

This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (+) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

The present invention provides lipase inhibitors containing dimers of flavan-3-ols derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of assamicains represented by the formula:wherein G represents a galloyl group;theasinensins represented by the formula:wherein R1 represents G or H, and R2 represents G; andtheaflavins represented by the formula:

The invention provides a preparation method of a microcapsule particle capable of adjusting the body fat percentage. The preparation method comprises the following steps: preparing core powder A; embedding the core powder A by slowly digestible starch emulsion, adding at least one of fibersol-2 and lipase inhibitor into starch embedded particles, evenly mixing to obtain core powder B; preparing capsule wall slurry: adding a proper amount of starch blocker into a mixed solution of sodium alginate and trehalose, evenly mixing to obtain capsule wall slurry; preparing the microcapsule particle: dispersing core powder B into a diluted solution of the capsule wall material to form a suspension liquid, and carrying out spray-drying to obtain the microcapsule particles. The invention also relatesto a preparation containing the microcapsule particle; such as capsule or food. The microcapsule particle is suitable for reducing the body fat percentage of patients of hyperlipidemia and fat peopleand has a good market value and potential for industrial production.